Epcoritamab plus R-CHOP cut the risk of progression or death by 51% in a Phase 3 DLBCL trial, per AbbVie and Genmab. Survival and full data are pending.
Topline Phase 3 Data Show Adding Epcoritamab to Standard R-CHOP Cut Lymphoma Progression or Death Risk by 51%
by | Oct 6, 2026 | Uncategorized | 0 comments
Recent Comments